Sall4 in "stemness"-driven hepatocarcinogenesis

New England Journal of Medicine

Volumn 368, Issue 24, 2013, Pages 2316-2318

  Marquardt, Jens U ^a,b   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RESMINOSTAT; SORAFENIB; TIVANTINIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; DISEASE MARKER; EDITORIAL; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE SILENCING; GENE TARGETING; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA INTERFERENCE; SALL4 GENE; TREATMENT INDICATION;

EID: 84878857836     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1303026     Document Type: Editorial

References (11)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Forner A, Llovet JM, Bruix J. Sunitinib and the benefits of a negative study. Lancet Oncol 2009;10:743-4.
4. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-61. (Pubitemid 44427449)
5. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-6.
6. Yang J, Chai L, Gao C, et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood 2008;112:805-13. [Erratum, Blood 2009;114:3131.]
7. Oikawa T, Kamiya A, Kakinuma S, et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology 2009;136:1000-11.
8. Yong KJ, Gao C, Lim JSJ, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013;368:2266-76.
9. Oikawa T, Kamiya A, Zeniya M, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 2013;57:1469-83.
10. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57:821-9.
11. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for secondline treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013;14:55-63.